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Background: ATP10D belongs to a subfamily of P-type ATPases implicated in phospholipids translocation
from the exoplasmic to the cytoplasmic leaﬂet of cellular biological membrane. Previous genome-wide
association study (GWAS) identiﬁed that a variant in Atp10d gene (rs2351791) associates with serum
lipid proﬁle and myocardial infarction. The objective of this study is to assess the effect of this variant on
atherosclerosis in Japanese elderly population.
Method: Consecutive autopsy cases registered in JG-SNP study were recruited (n ¼ 1536). The samples
were pathologically assessed for atherosclerosis using macroscopic examination of the formalin-ﬁxed
arteries, and coronary stenotic index (CSI), intracranial atherosclerotic index (ICAI) and pathological
atherosclerotic index (PAI), which represent systemic arteries were calculated. The variant rs2351791
(G/T) in Atp10d gene was genotyped by Taqman genotyping assay and association determined.
Result: Both CSI and ICAI were signiﬁcantly higher in GG genotype than GT genotype and TT genotype
(p ¼ 0.003 and p ¼ 0.001, respectively). Both associations remained signiﬁcant in minor allele dominant
model after adjusting for age, hypertension, diabetes, HDL, smoking and drinking (p ¼ 0.001 and
p ¼ 0.001, respectively). PAI was not associated with this variant. Consistent with the previous report,
plasma HDL cholesterol level was lower in GG genotype compared to GT þ TT genotypes (p ¼ 0.001).
Conclusion: The rs2351791 SNP in the Atp10d gene affects the susceptibility for cardiac and intracranial
vascular stenosis in the elderly Japanese population.
 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
According to WHO estimates, ischemic heart diseases and ce-
rebrovascular diseases are the two leading causes of mortality
worldwide [1]. The disease is caused by atherosclerosis which is,; CSI, cardiac stenotic index;
ogical atherosclerotic index;
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Muramatsu).
r Ireland Ltd Open access under CC B.formed by vascular stiffening initiated by focal asymmetrical
thickening and hardening in the intima, from plaque due to cell
debris and lipid accumulation [1]. Chronic inﬂammation is one of
the causes of disease formation that produces pro-inﬂammatory
cytokines enhancing the plaque enlargement [2]. The disease is
also associated with certain lifestyle characteristics and to date a
large body of scientiﬁc literature has established that tobacco use,
unhealthy diet, physical inactivity, raised blood pressure, raised
blood cholesterol, obesity, diabetes and psychosocial factors [3].
Besides these risk factors, genetic role had also been strongly
implicated in the pathogenesis of vascular diseases [4], which ac-
counts for 38% of the disease development [5]. Lipid metabolism
especially LDL level elevation and conversely low level of HDL
concentration are mainly involved in disease development and
progression [6].
ATP10D is a member of P4-ATPases (subfamily IV P-type ATPa-
ses), a specialized subfamily of P-type ATPases implicated in.Y-NC-ND license.
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plasmic leaﬂet of biological membrane. This function is essential for
maintenance of lipid imbalance in biological membrane structures
and this group of translocases belongs to a group of proteins, called
aminophospholipid translocases (APLTs), or Flippases [7]. Though
not exactly, known APLTs activity is thought to be associated with
the formation of asymmetric membrane structure through pump-
ing phosphatidylethanolamine (PE) and phosphatidylserine (PS)
from the external/luminal leaﬂet of the plasma membrane to the
inner/cytosolic leaﬂet in an ATP dependent manner [7e9], and
therefore along with phospholipid scramblases and ﬂoppases en-
hances membrane stability [8]. Furthermore, this attribute of P-
type ATPases facilitates the formation of exocytic and endocytic
vesicles linked to protein transport [9]. In additional, multiple
studies of simple and complex multicellular organisms had shown
that P-type ATPases facilitate growth in permissive temperature,
sterol metabolism [8,9] and ribosome assembly and function [8,10].
Allowing to a conserved role through evolution as such it may have
critical roles in maintaining cellular homeostasis.
Studies in mice for Atp10d; C57BL/6J strain were shown to carry
a constitutive stop codon in the sequence of Atp10d exon 12 [11].
Interestingly, C57BL/6J mice developed obesity, hyperglycemia, and
hypertension when fed a high fat diet [12,13]. Also Atp10d was
reported as a candidate gene that modulates plasma HDL choles-
terol level [14]. In humans GWAS reports had identiﬁed Atp10d
variants among other genes signiﬁcantly associated with circu-
lating sphingolipids (Glucosylceramides and ceramides) species
levels and HDL. The SNP rs2351791 located in intronic region of
Atp10d gene in chromosome 4p12 [15] was also shown signiﬁ-
cantly associated with myocardial infarction in German population.
Atp10d gene and its role in the etiology of cardiovascular diseases
had been studied [15], but more still needed to be investigated due
to the highly complex nature of genetic risks and cardiovascular
disease pathogenesis.
The main objective of our study is to assess the effect of Atp10d
gene polymorphism on coronary and intracranial vascular stenosis
in the elderly Japanese population. Secondly, we aimed to explore
whether the Atp10d gene polymorphism associate with plasma
HDL cholesterol level or not in the population.
2. Materials and methods
2.1. Study subjects
Total subjects of 1536 autopsy cases obtained from Tokyo
Metropolitan Geriatric Hospital from 1995 to 2003 were included
in this study. All the subjects were Japanese. The details of the
autopsy cases are described elsewhere [16e18], and referred as
“The Japanese SNP database for geriatric research (JG-SNP)”. JG-SNP
was created by adding the data of genetic polymorphism, based on
the clinical and pathological information of the autopsy database,
performed in Tokyo Metropolitan Geriatric Hospital. The JG-SNP
contains clinical diagnoses for 26 geriatric diseases, 42 patholog-
ical diagnoses and genetic polymorphism. The JG-SNP databasewas
performed to investigate the roles of genetic polymorphisms in
geriatric diseases.
The clinical parameters were obtained retrospectively from
medical charts at the time of either admission or in the outpatient
clinic. Hypertension was diagnosed based on usual medical practice
deﬁnition as repeated elevation of systolic blood pressure > 140
mmHg or diastolic blood pressure > 90 mmHg. Diabetes was diag-
nosed as, fasting plasma glucose > 126 mg/dL, or a casual plasma
glucose> 200 mg/dL or if the 2 h blood glucose level in the 75-g oral
glucose tolerance test was 200 mg/dL, according to the guidelines
issued by the Japan Diabetes Society in 1998. BMI was obtained bydirect measurement of height and weight. Obesity was diagnosed as
BMI  25 according to the Japan Society for the Study of Obesity
(JASSO). HDL cholesterol level was measured by conventional pre-
cipitation method and total cholesterol level measured by enzymatic
cholesterol assay method. Information on drinking and smoking
statuswas obtained from themedical records. In order to input in the
regression analysis, we prepared dichotomous variable for smokers
and drinkers as 1, otherwise 0. The study had been approved by the
ethical committees of Tokyo Metropolitan Geriatric Hospital, Japan
and Tokyo Medical and Dental University, Japan.
2.2. Pathological assessment of the atherosclerosis
We measured the atherosclerotic severity of the whole body by
dividing into three indices, termed coronary stenotic index (CSI),
intracranial atherosclerotic index (ICAI) and pathological athero-
sclerotic index (PAI). To assess the vascular stenotic level near the
coronary area, the coronary stenotic index (CSI) was measured. CSI
was examined by using transverse sections at 5 mm intervals [19].
The degree of coronary stenosis was scored from 0 to 5: [(0: no
sclerosis, 1: slight stenosis, 2: 25% stenosis, 3: 50%, 4: 75%, and 5:
100% obstructions)]. CSI was the sum of the stenotic scores of the
three branches: left anterior descending branch, left circumﬂex
branch, and right coronary artery. The intracranial atherosclerotic
index (ICAI) was measured for vascular stenotic level near intra-
cranial part. ICAI was established by observing the cut sections of
the intracranial arteries and scoring the degree of stenosis from 0 to
3: [(0: no stenosis, 0.5: cases with only fatty streaks, 1: <50% ste-
nosis, 2: 50e90% stenosis, 3: 90% stenosis to occlusion)]. The
intracranial atherosclerotic index (ICAI) is the sum of the stenotic
scores of the left and right middle cerebral arteries and basilar ar-
teries [20].
The severity of atherosclerosis assessment has been previously
reported elsewhere [17]. To determine the systemic atherosclerosis,
eight large arteries were measured. They are the common carotid
artery, subclavian artery, aorta, splenic artery, superior mesenteric
artery, common iliac artery, external iliac artery, and femoral artery.
Each artery was evaluated by macroscopic examination of the
luminal surface in the formalin-ﬁxed arteries. The degree of
atherosclerosis was scored according to the ratio of the occupying
atheroma to the entire intimal area: 0e8: [0 (absent, <1/20 of the
intimal areas occupied by the atheroma), 2 (minimal, 1/20e1/6), 4
(mild, 1/6e1/3), 6 (moderate, 1/3e2/3) to 8 (severe, 2/3e1)]. The
pathological atherosclerotic index (PAI) was deﬁned as the average
atherosclerotic degree of these eight arteries.
In order to ensure our accuracy and validity in pathological as-
sessments, all internal organs were extirpated, examined and ﬁxed
in 10% formalin. Weekly conferences were held and the macro-
scopic re-examinations of extirpated organs were performed. With
the results of microscopic examinations, all cases were presented
and discussed in details with clinicians at weekly conferences. All
initial data were taken from the gross and microscopic autopsy
reports and entered into the free-text type autopsy database [18].
2.3. Genotyping
DNA samples were extracted from the renal cortex by the phenol/
chloroform method. The PCR primers and hybridization probes were
obtained by ordering through Applied Biosystems (Foster City, CA,
USA). Putative SNPs in the Atp10d genes were brieﬂy identiﬁed from
the literatures and SNP databases (www.ncbi.nlm.nih.gov). The
thermal cycling conditions were 95 C for 10 min (DNA melting
temperature), and then 40 cycles at 92 C for 15 s, 60 C for 1 min
(strand melting, extension and re-annealing temperatures respec-
tively). The ampliﬁcation cycle was performed on a GeneAmp PCR
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cation, the genotypes of SNP (rs2351791) in Atp10d gene were
determined by TaqMan allelic discrimination assay with a commer-
cial kit (Light Cycler, Roche, Penzberg, Germany) according to the
manufacturer’s instructions. SNP call rates more than 95% were used
in allelic discrimination procedure in this study.
2.4. Statistical analysis
Data were analyzed by Student’s t-test and analysis of variance
(ANOVA), expressed as the mean  SD (standard deviation).
HardyeWeinberg equilibrium was performed to test the distribu-
tion for genotyping result. To account for multiple risk factors that
affect the level of atherosclerosis, regression analysis was per-
formed with adjustment for age, hypertension, diabetes, plasma
HDL cholesterol level, all the categories of smoking and drinking.
Bonferroni’s correctionwas tested for multiple comparisons. All the
analysis were performed by the Statistical Package for the Social
Sciences forWindows, version 19.0 (IBM SPSS Statistics Desktop for
Japan). p < 0.05 was considered statistically signiﬁcant.
3. Results
Initially, the total subjects in the study include of 1536. We
excluded 139 subjects because of not available adequate clinical
history (n ¼ 2), blood parameter (n ¼ 13), pathological assessment
(n ¼ 34) and lack of DNA or undetermined genotyping (n ¼ 90).
Finally, 1397 subjects were included in our study.
Table 1 shows the clinicalepathological assessment of the study
subjects according to the genotype status. Age, plasma HDL
cholesterol level, CSI, ICAI and PAI are statistically signiﬁcant among
the three genotype groups (p ¼ 0.037, p ¼ 0.001, p ¼ 0.003,
p ¼ 0.001 and p ¼ 0.037 respectively). GG genotype possessing
subjects have lower plasma HDL cholesterol level, subsequently
higher in both CSI and ICAI than GT and TT genotype groups
(Table 1). The distribution for the genotyping result was calculated
by chi-square test for deviation of HardyeWeinberg equilibrium.
The distribution for genotyping result was under HardyeWeinberg
equilibrium with p ¼ 0.1377 shown in Table 2. In the minor allele
dominant model (GG vs GT þ TT), CSI and ICAI were signiﬁcantly
higher in GG genotype group (p¼ 0.001 (b ¼ 0.115) and p ¼ 0.001
(b ¼ 0.140) respectively) performed by linear regression analysis
adjusted for age, hypertension, diabetes, plasma HDL cholesterol
level, smoking and drinking (Table 3). But, conversely, PAI is
signiﬁcantly lower in GG genotype group in the same model in our
study (p ¼ 0.032, b ¼ 0.058). In addition, when we applied Bon-
ferroni’s correction for multiple testing of three separateTable 1
Clinico-pathological assessment of the study subjects.
Atp10d, rs2351791 GG GT
n Mean  SD n
Age (year) 837 80.63  8.82 501
BMI (kg/m2) 833 17.13  3.68 499
TC (mg/dL) 658 164.40  43.79 414
HDL (mg/dL) 630 40.48  14.73 409
CSI 831 8.54  3.42 496
ICAI 699 2.98  2.12 381
PAI 779 4.12  1.60 444
Hypertension 837 202 (24.13%) 501
Diabetes 837 111 (13.26%) 501
History of smoking 764 374 (48.95%) 474
History of drinking 764 271 (35.47%) 468
Continuous variables are analyzed by analysis of variance (ANOVA) test, expressed as m
Categorical variables are analyzed by Chi-squared test, expressed as number and percenphenotypes; CSI and ICAI remain positive (p ¼ 0.003) and
(p < 0.001 respectively), while PAI (p ¼ 0.037), no longer remained
signiﬁcant.
Further, we tested for plasma HDL cholesterol level and the
mean plasma HDL cholesterol level showed signiﬁcantly lower in
GG genotype group (40.48  14.73) than GT þ TT genotype group
(45.30  17.03) with (p ¼ 0.001) performed by students’ t test as
shown in Fig. 1.4. Discussion
Atherosclerotic diseases in particular coronary and cerebral
vascular diseases are major causes of death around the world [1].
Genetic association studies provide opportunities to be wider in
understanding of genetic risk factors associated with the devel-
opment of complex traits of interest [21]. In this article, we
provide evidence of genetic association of Atp10d gene poly-
morphism with plasma HDL cholesterol level and atherosclerotic
disease measured in (CSI, ICAI and PAI) in Japanese elderly
population.
Atp10d belongs to the P4 ATPase family of phospholipid trans-
locases with a role in human diseases [7]. Previously, genome wide
association study revealed signiﬁcant association of Atp10d poly-
morphisms (rs10938494 and rs2351791) with circulating ceramide,
glucosylceramide species levels and myocardial infarction [15].
Therefore, Atp10d is a ceramide inward translocase at the biological
membrane and functional changes of Atp10d activity may result in
enhanced cytosolic ceramide concentrations leading to accelerated
ceramide glucosylation and elevated serum glucosylceramide [22].
Sphingolipids species (ceramide and glucosylceramide) are
known to be pathogenic lipids in human and have been linked to
play a role in the pathogenesis of atherosclerosis. Sphingolipids
promote atherosclerosis and thrombosis in a number of different
ways. Firstly, ceramides have a strong tendency to self-aggregate,
that may contribute to the amalgamation of ceramide-enriched
LDL (low density lipoproteins). Secondly, ceramides can induce
apoptosis in vascular cell wall, thus contributing to plaque erosion
that can induce thrombosis. Thirdly, by blocking access to apoE
(apolipoprotein E) and lipoprotein lipase, sphingomyelin may block
LDL (low density lipoproteins) uptake. Fourthly, S1P (sphingosine1-
phosphate) stimulates endothelial and smooth muscle cell prolif-
eration, thus contributing to thickening of the vascular wall and
plaque stabilization. Fifthly, ceramide may regulate the synthesis of
PAI-1 (plasminogen activator inhibitor 1), which contributes to
atherosclerosis and thrombosis [23]. In direct experiments, both
in vitro and animals models demonstrated involvements of cer-
amide in ischemic death of myocardial cells [24]. It is therefore,TT p
Mean  SD n Mean  SD
79.38  8.92 59 80.78  8.32 0.037
17.24  3.59 59 17.01  3.69 0.815
166.84  45.44 46 166.00  50.26 0.681
45.40  17.12 43 44.37  16.29 <0.001
7.84  3.95 58 8.13  3.53 0.003
2.37  2.04 47 1.86  2.02 <0.001
4.36  1.56 51 4.10  1.65 0.037
176 (35.12%) 59 13 (22.03%) 0.001
79 (15.76%) 59 11 (18.64%) 0.286
255 (54.48%) 54 29 (53.70%) 0.361
168 (35.89%) 52 23 (44.23%) 0.654
ean  standard deviation.
tage (%) of disease.
Table 2
Genotyping result.
Atp10d, rs2351791 rs2351791(G/T) MAF (T) our study p for HeW
Total GG GT TT
Total subjects 1397 837 (59.91) 501 (35.86) 59 (4.22) 0.22 0.1377
Male subjects 755 429 (56.82) 293 (38.80) 33 (4.37) 0.23 0.0520
Female subjects 642 408 (63.55) 208 (32.39) 26 (4.04) 0.20 0.9372
MAF, minor allele frequency.
Table 3
Minor allele dominant model.
Atp10d, rs2351791 GG GT þ TT p* p** py
n Mean  SD n Mean  SD
CSI 831 8.54  3.42 554 7.87  3.91 0.001 0.003 0.001 (b ¼ 0.115)
ICAI 699 2.98  2.12 428 2.32  2.04 0.001 0.001 0.001 (b ¼ 0.140)
PAI 779 4.12  1.60 495 4.33  1.57 0.019 0.037 0.032 (b ¼ 0.058)
*Value by students’ t test.
**Value by multiple testing (Bonferroni’s correction).
yValue by liner regression test adjusting for age, hypertension, diabetes, plasma HDL cholesterol level, smoking & drinking.
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atherosclerotic diseases through modulation of cytosolic patho-
genic syphingolipids species. Our ﬁndings in Atp10d genetic poly-
morphism with atherosclerotic disease (Tables 1 and 3) could
therefore be explained by this proposed role of Atp10d modulation
of cytosolic pathogenic syphingolipids species.
Since Atp10d gene was proposed as a marker for regulation of
plasma HDL cholesterol level [14], therefore, it is considered to be a
marker for atherosclerosis through indirect effects. However, each
sample in our study has been measured for plasma HDL cholesterol
level and our analysis was performed by adjusting age, hyperten-
sion, diabetes, HDL, smoking and drinking; thus, it is conceivable
that there is an independent effect of Atp10d polymorphism on
atherosclerosis. Nevertheless, we should not look over the effect of
these dependent factors, due to undiscovered and complex nature
of etiology of atherosclerosis.
Our ﬁndings in the minor allele dominant model however, in
which ICAI and CSI were signiﬁcantly higher in GG genotype while
PAI is signiﬁcantly lower in the same genotype that suggests siteFig. 1. Comparison of plasma HDL cholesterol level (dominant model).speciﬁcity of the effect of genetic polymorphism in the pathogen-
esis of atherosclerotic diseases. Indeed, in our previous study, we
had demonstrated a differential effect of genetic polymorphisms in
different arteries. Therefore, our ﬁnding is consistent with previous
research and postulated that different polymorphisms account for
different site of atherosclerotic disease [16]. However, the devel-
opment of atherosclerosis disease is affected by a number of factors,
for instance, the blood ﬂow, anatomy of the vessels and shear stress
[25,26]. We therefore hypothesize that site speciﬁc gene poly-
morphism interacts with artery-speciﬁc factors to affect a sequelae
of atherosclerotic disease.
We have also shown that Atp10d polymorphism is signiﬁcantly
associated with HDL concentration. This ﬁnding is consistent with
previous studies [15], and also in mice it has been shown that
Atp10d is located in a genomic region associated with HDL mod-
ulation [27]. LowHDL and conversely high LDL had been implicated
in the literature to increase risks of atherosclerosis diseases [28].
Our ﬁndings in the association of Atp10d polymorphism with low
plasma HDL cholesterol level (Table 1 & Fig. 1) and previous studies
that implicated Atp10d polymorphism with circulating syph-
ingolipids species levels suggest that Atp10d polymorphism leads
into atherosclerosis through multiple complex pathways involving
Atp10d SNPs modulation of intermediate phenotypes.
There are some limitations in our study. Due to the character-
istics of our sample, we could not get sufﬁcient clinical data related
to circulating sphingolipids (ceramides and glucosylceramides) in
supporting of our conceived hypothesis that Atp10d polymorphism
lead into atherosclerosis through modulation of cytosolic patho-
genic sphingolipids species levels. Death related to severe athero-
sclerosis at early age might result in non-inclusion amongst our
study subjects and predispose to survival bias, and also we per-
formed experiments for only one type of SNP. Nevertheless, our
study used autopsy cases that provide a unique opportunity for
investigating the effect of genetic polymorphism in undiagnosed
conditions [18].
In conclusion we have shown that rs2351791 SNP in Atp10d
gene is associated with cardiac and intracranial vascular stenosis in
the Japanese elderly population and also, it was associated with
reduced plasma HDL cholesterol level. Atp10d appears to be a good
candidate for investigation of vascular diseases and it is especially
interesting to investigate Atp10d polymorphism as a biomarker in
detecting coronary and cerebrovascular diseases.
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